Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib

被引：8
|
作者：
Fujioka, Shusei [1 ]
Kitajima, Takamasa [1 ]
Itotani, Ryo [1 ]
机构：
[1] Kitano Hosp, Tazuke Kofukai Med Res Inst, Resp Dis Ctr, Div Resp Med, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 08期
关键词：
D O I：
10.1016/j.jtho.2018.03.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E137 / E139
页数：4
相关论文
共 50 条
  • [41] Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature
    Ferrazzi, Anna
    Russo, Irene
    Pasello, Giulia
    Alaibac, Mauro
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 11 (01) : 197 - 200
  • [42] Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib
    Masutani, Kohsuke
    Fujisaki, Kiichiro
    Maeda, Hiroto
    Toyonaga, Jiro
    Inoshima, Ichiro
    Takayama, Koichi
    Katafuchi, Ritsuko
    Hirakata, Hideki
    Tsuruya, Kazuhiko
    Iida, Mitsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2008, 12 (05) : 398 - 402
  • [43] Massive Hematuria from the Bilateral Upper Urinary Tract in a Patient Treated for Advanced Lung Cancer with Gefitinib
    Mori, Hidenori
    Ohno, Yasushi
    Ito, Fumitaka
    Funaguchi, Norihiko
    Yanase, Komei
    Endo, Junki
    Nakano, Masahiro
    La, Bu Lin Bai
    Minatoguchi, Shinya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (03) : 263 - 266
  • [44] How to overcome and circumvent acquired resistance to osimertinib or lazertinib in advanced EGFR mutant lung cancer?
    Cho, Byoung Chul
    ANNALS OF ONCOLOGY, 2023, 34 : S1378 - S1378
  • [45] A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed
    Takano, Natsuki
    Seike, Masahiro
    Sugano, Teppei
    Matsuda, Kuniko
    Hisakane, Kakeru
    Yoshikawa, Akiko
    Nakamichi, Shinji
    Noro, Rintaro
    Gemma, Akihiko
    ANTICANCER RESEARCH, 2022, 42 (02) : 709 - 722
  • [46] Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
    Satoh, Shingo
    Shiroyama, Takayuki
    Tamiya, Motohiro
    Nasu, Shingo
    Tanaka, Ayako
    Morita, Satomu
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Hirashima, Tomonori
    RESPIRATORY MEDICINE CASE REPORTS, 2018, 23 : 68 - 70
  • [47] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
  • [48] METamplification results in heterogeneous responses to osimertinib inEGFR-mutant lung cancer treated with erlotinib
    Nishiyama, Akihiro
    Takeuchi, Shinji
    Adachi, Yuta
    Otani, Sakiko
    Tanimoto, Azusa
    Sasaki, Motoko
    Matsumoto, Shingo
    Goto, Koichi
    Yano, Seiji
    CANCER SCIENCE, 2020, 111 (10) : 3813 - 3823
  • [49] Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer
    Novello, Silvia
    Rudell, Katja
    Bodnar, Carolyn
    Vowler, Sarah
    Rupnik, Tina
    Ghiorghiu, Serban
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1238 - S1239
  • [50] Patient Care in Advanced Lung Cancer: Unmet Needs
    Morere, J.
    Eisinger, F.
    Naman, H.
    Sellami, R.
    Lhomel, C.
    Ganem, G.
    Viguier, J.
    Simon, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S824 - S824
12345